PepBank has 2 petrelintide studies with results. Both of them gave petrelintide, with 22 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.
Searches 22 results and 8 papers. Newer studies from Europe PMC
Identifiers, parent molecule, targets and development stage, from curated data.
Petrelintide, formerly ZP8396, is a modified human amylin analog. Its development addresses peptide stability and prolonged action. It differs from pramlintide, cagrilintide and GLP-1 receptor agonists.
| Target | Action | Evidence |
|---|---|---|
| Calcitonin receptor and amylin receptor complexesCALCRP30988 (opens in a new tab) | Agonist | Peptide 40 activated human CTR and human AMY3R in cAMP assays.Source (opens in a new tab) |
Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.
Sequence not disclosed
The primary paper identifies petrelintide as peptide 40. It deletes amylin residues 21 and 22, leaving 35 backbone residues. The gamma-glutamyl linker gives 36 amino-acid residues in total, consistent with the developer poster. The patent supplies the displayed modified sequence. PubChem supplies the formula and computed masses. Its IUPAC name assigns (2S,4S) hydroxyproline, whereas the primary paper and patent specify (2S,4R). SMILES and InChIKey remain null pending reconciliation. No machine structure was inferred. A later clinical paper calls the peptide 37 residues, which conflicts with the explicit chemical sequence.
No sequence is listed for the parent, so no alignment is shown.The primary paper derives peptide 40 from human amylin through substitutions and deletion of positions 21 and 22. This is not one unchanged contiguous parent segment. UniProt P10997 identifies human amylin.
No sequence is listed, so nothing can be calculated.
No charge curve
No sequence is listed for this peptide.
No sequence is listed for this peptide.
Loads the 3D viewer (3Dmol.js, about 150 KB) and the model file from AlphaFold DB (EMBL-EBI).
People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.
PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.
Counts are exact and come from studies that gave the peptide.
Studies by year
2 of 8 studies have results (25%), published 2026. Top row: every study. Bottom row: studies with results about Petrelintide, by class. The rows use different scales.
Studies8 in all, 2025 to 2026
Studies with results2 in all, 2026
Retracted studies are left out. A study with results in two classes counts in both.
AI wrote and checked these results. AI can make mistakes, so check important results against the source.
Registered trials that test the peptide, with phase, status and dates. A dot marks trials with posted results.
12 trials match. Highest phase first. Data from ClinicalTrials.gov.
12 trials · 5 ongoing · 1 not yet recruiting · 6 completed
A First-in-human Study Looking at the Safety of ZP8396 and How it Works in the Body of Healthy Trial Participants
NCT0509659819 Oct 2021 to 12 Jan 2023
A Research Study Looking at the Safety of Multiple Doses of ZP8396 and How it Works in the Body of Healthy Participants
NCT056133877 Nov 2022 to 13 Jun 2024
Phase II Clinical Trial to Evaluate the Efficacy and Safety of NV01-A02 in Children With Autism Spectrum Disorder
NCT069518541 Apr 2025 to est. 1 Dec 2026
Pharmacokinetics of Petrelintide Following Administration to Participants With Impaired Renal Function
NCT0707603015 Apr 2025 to 25 Nov 2025
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
NCT0692684222 Apr 2025 to 13 Aug 2026
Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product Concentrations
NCT0733821417 Dec 2025 to 31 Mar 2026
Pharmacokinetics of Petrelintide in Participants With Impaired Hepatic Function
NCT0768281818 May 2026 to est. 12 Apr 2027
12 trials · 5 ongoing · 1 not yet recruiting · 6 completed · source ClinicalTrials.gov (opens in a new tab)
Hoffmann-La Rochen = 2,50030 Sept 2026 to est. 6 Oct 2030
Obesity or Overweight · Cardiovascular Disease
Hoffmann-La Rochen = 600est. 30 Sept 2026 to est. 19 Jan 2029
Obesity or Overweight · Type 2 Diabetes
Hoffmann-La Rochen = 3,90030 Sept 2026 to est. 22 Mar 2029
Obesity or Overweight
Zealand Pharman = 22122 Apr 2025 to 13 Aug 2026
Overweight · Type 2 Diabetes · Obesity
Hoffmann-La Rochen = 486est. 30 Sept 2026 to est. 31 Jan 2028
Obesity or Overweight
Zealand Pharman = 4939 Dec 2024 to 7 Mar 2026
Obesity
Neuroventi Inc.n = 1051 Apr 2025 to est. 1 Dec 2026
Autism Spectrum Disorder (ASD
Zealand Pharman = 3618 May 2026 to est. 12 Apr 2027
Impaired Hepatic Function
Zealand Pharman = 4817 Dec 2025 to 31 Mar 2026
Obesity & Overweight
Zealand Pharman = 3915 Apr 2025 to 25 Nov 2025
Renal Impairment
Zealand Pharman = 687 Nov 2022 to 13 Jun 2024
Overweight · Healthy Volunteers · Obese
Zealand Pharman = 6419 Oct 2021 to 12 Jan 2023
Overweight · Healthy Volunteers
Studies on this peptide. Some have results. The others have none yet.
8 studies match. Retracted studies are left out.
Showing 2 of 8 studiesquery qry_72422873871d9c3486cf7567
2 studies
Randomized controlled trial · 2026
Brændholt Olsen et al. 2026Diabetes, obesity & metabolismcited by 2
PMID 42017294PMC13243934DOI 10.1111/dom.70753PUB-42017294
Randomized controlled trial · 2026
Garvey et al. 2026The lancet. Diabetes & endocrinologyn = 485
PMID 42810355DOI 10.1016/s2213-8587(26)00213-5PUB-42810355
These studies name Petrelintide but give no result for it (for example, the results concern another peptide in the study).
PubMed tag: none · 2025
Fischer Munch et al. 2025Journal of medicinal chemistrycited by 12
PMID 41217931PMC12670398DOI 10.1021/acs.jmedchem.5c01185PUB-41217931
PubMed tag: none · 2025
Zong et al. 2025Journal of medicinal chemistrycited by 6
PMID 40608546DOI 10.1021/acs.jmedchem.5c01120PUB-40608546
PubMed tag: Review · 2026
Rejili et al. 2026Vascular pharmacologycited by 3
PMID 41344603DOI 10.1016/j.vph.2025.107563PUB-41344603
PubMed tag: Review · 2026
Bailey et al. 2026Peptidescited by 2
PMID 41747885DOI 10.1016/j.peptides.2026.171480PUB-41747885
PubMed tag: Review · 2026
Alhazmi et al. 2026Diabetes, obesity & metabolismcited by 1
PMID 42452898PMC13588232DOI 10.1111/dom.71074PUB-42452898
PubMed tag: Review · 2026
Fischer et al. 2026Pharmacological research
PMID 42586227DOI 10.1016/j.phrs.2026.108382PUB-42586227
Page 1 of 1
Garvey WT · The lancet. Diabetes & endocrinology · 2026
Randomized controlled trial · 11 results
Brændholt Olsen M · Diabetes, obesity & metabolism · 2026
Randomized controlled trial · 11 results
Approval and sport status, and the safety outcomes reported in study results. Laws and labels change, so check the regulator for the current status.
| Jurisdiction | Body | Status | As of | Source |
|---|---|---|---|---|
| US | FDA | The developer states that petrelintide has no marketing approval from any regulatory authority. No product-specific agency approval record was established. This includes national approval. UNII assignment does not imply approval. | 27 Oct 2026 | zealandpharma.com (opens in a new tab) |
| EU | EMA | The developer states that petrelintide has no marketing approval from any regulatory authority. No product-specific agency approval record was established. This includes national approval. UNII assignment does not imply approval. | 27 Oct 2026 | zealandpharma.com (opens in a new tab) |
| Sport | WADA | Banned in sport (WADA S0) S0 prohibits pharmacological substances without governmental approval for human therapeutic use at all times. | 2026 List | wada-ama.org (opens in a new tab) |
12 safety results for Petrelintide.
In eligible adults with overweight or obesity, nausea occurred in 79 of 404 petrelintide recipients (20%) versus five placebo recipients (6%).
Randomized controlled trialn = 485
In eligible adults with overweight or obesity, vomiting occurred in 12 petrelintide recipients (3%) versus five placebo recipients (6%).
Randomized controlled trialn = 485
In eligible adults with overweight or obesity, diarrhoea rates were similarly low with petrelintide (30 participants, 7%) and placebo (six participants, 7%).
Randomized controlled trialn = 485
In eligible adults with overweight or obesity, constipation rates were similarly low with petrelintide (28 participants, 7%) and placebo (three participants, 4%).
Randomized controlled trialn = 485
In the obesity trial, no deaths were reported, including during petrelintide treatment.
Randomized controlled trialn = 404
In phase 1 participants receiving petrelintide, no serious treatment-emergent adverse events occurred.
Randomized controlled trialn not reported
In phase 1 participants receiving petrelintide, no severe treatment-emergent adverse events occurred.
Randomized controlled trialn not reported
In phase 1 participants, gastrointestinal disorders were among the most common petrelintide adverse events and were mostly mild.
Randomized controlled trialn not reported
The doses that these studies used. They are not recommendations.
5·0 mg once weeklyHuman
9·0 mg once weeklyHuman
2·5 mg once weeklyHuman
1·0 mg once weeklyHuman
7·0 mg once weeklyHuman
PepBank is a research reference. Talk to a doctor before you use any peptide.
Data version, change history and code for this peptide.
curl -s https://Evidence summary for Petrelintide: counts by class, key results with sources, notices, data version.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Top outcomes
The 5 outcome groups with the most study results, by evidence class.
Data version 308560. Bar length is the number of results, not the size of an effect.
Evidence matrix
Study results by outcome and evidence class. Arrows show how the measured outcome moved, not whether the change is good.
| Outcome group | Human | Animal | Lab | Computer model | Total |
|---|---|---|---|---|---|
| Gastrointestinal adverse eventsGastrointestinal | Human: 9 results from 2 studies: 1 increase, 1 decrease, 2 no significant change, 5 not reported. Strongest design: Randomized controlled trial | No results | No results | No results | 9 |
| Body weightMetabolic and weight | Human: 7 results from 2 studies: 7 decrease. Strongest design: Randomized controlled trial | No results | No results | No results | 7 |
| PharmacokineticsPharmacology | Human: 3 results from 1 study: 3 not reported. Strongest design: Randomized controlled trial | No results | No results | No results | 3 |
| Adverse eventsWhole body | Human: 2 results from 1 study: 2 not reported. Strongest design: Randomized controlled trial | No results | No results | No results | 2 |
| MortalityWhole body | Human: 1 result from 1 study: 1 not reported. Strongest design: Randomized controlled trial | No results | No results | No results | 1 |
5 outcome groups shown of 5 · 22 study results
Data version 308560. Shade grows with the number of results. Every cell shows the exact count.
Trials by phase
12 registered trials, grouped by phase and shown by status.
Source: ClinicalTrials.gov, data version 308560. Status is the registry status.